Ladanyi M - Search Results

1

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. D'Angelo SP, et al. Among authors: ladanyi m. J Thorac Oncol. 2012 Dec;7(12):1815-1822. doi: 10.1097/JTO.0b013e31826bb7b2. J Thorac Oncol. 2012. PMID: 23154553 Free article.

2

Detection of BCL2 rearrangement in archival cytological smears of B-cell lymphomas.

Shivnarain D, Ladanyi M, Zakowski MF. Shivnarain D, et al. Among authors: ladanyi m. Mod Pathol. 1994 Dec;7(9):915-9. Mod Pathol. 1994. PMID: 7892160

3

p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.

Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. Lonardo F, et al. Among authors: ladanyi m. Cancer. 1997 Apr 15;79(8):1541-7. Cancer. 1997. PMID: 9118036

4

Detection of the SYT-SSX chimeric RNA of synovial sarcoma in paraffin-embedded tissue and its application in problematic cases.

Argani P, Zakowski MF, Klimstra DS, Rosai J, Ladanyi M. Argani P, et al. Among authors: ladanyi m. Mod Pathol. 1998 Jan;11(1):65-71. Mod Pathol. 1998. PMID: 9556426

5

Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies.

Gu M, Antonescu CR, Guiter G, Huvos AG, Ladanyi M, Zakowski MF. Gu M, et al. Among authors: ladanyi m. Am J Surg Pathol. 2000 Mar;24(3):410-6. doi: 10.1097/00000478-200003000-00010. Am J Surg Pathol. 2000. PMID: 10716155

6

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O. Ladanyi M, et al. Cancer Res. 2002 Jan 1;62(1):135-40. Cancer Res. 2002. PMID: 11782370

7

The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.

Illei PB, Ladanyi M, Rusch VW, Zakowski MF. Illei PB, et al. Among authors: ladanyi m. Cancer. 2003 Feb 25;99(1):51-6. doi: 10.1002/cncr.10923. Cancer. 2003. PMID: 12589646 Free article. Clinical Trial.

8

Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.

Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Illei PB, et al. Among authors: ladanyi m. Clin Cancer Res. 2003 Jun;9(6):2108-13. Clin Cancer Res. 2003. PMID: 12796375

9

Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids.

López-Ríos F, Illei PB, Rusch V, Ladanyi M. López-Ríos F, et al. Among authors: ladanyi m. Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66. doi: 10.1016/S0140-6736(04)17102-X. Lancet. 2004. PMID: 15451223

10

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. Pao W, et al. Among authors: ladanyi m. PLoS Med. 2005 Jan;2(1):e17. doi: 10.1371/journal.pmed.0020017. Epub 2005 Jan 25. PLoS Med. 2005. PMID: 15696205 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

751 results

Search Page

Filters